Reviewing Case Studies to Understand How ADC Design Influences Early-Stage Clinical Outcomes - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Reviewing Case Studies to Understand How ADC Design Influences Early-Stage Clinical Outcomes

11:00 am - Wednesday 14th October 2026

Evaluating opportunities for ADCs with novel design to deliver differentiated clinical outcomes
Reviewing early-stage clinical results from LCB14 to understand the impact of bioconjugation and linker within the HER2 targeting ADC space
Delving into the early clinical profile of LCB71, a pro-PBD bearing ROR1 targeting ADC, demonstrating differentiated clinical safety and efficacy

Speakers:

Stephen Slocum

Stephen Slocum

Director - Drug Development, Project Lead

LigaChem Biosciences